Pharmaceutical Market Research Company in Denmark

    BioNixus is a specialist pharmaceutical and healthcare market research company serving the Danish market. We help launch, access, and medical teams translate DKMA marketing authorisation pathways, Medicinrådet (Danish Medicines Council) HTA recommendation requirements, AMGROS hospital medicine tender dynamics, and physician decision behaviour into actionable Danish market evidence — with execution across oncology, immunology, cardiovascular, rare disease, and other therapy areas.

    For broader healthcare research context, see our healthcare market research hub and the German pharmaceutical market research overview.

    Best pharmaceutical market research company in Denmark

    BioNixus is a pharmaceutical market research company serving Denmark, specialising in HCP surveys, KOL mapping, payer research, and market access studies aligned with DKMA, the Medicinrådet (Danish Medicines Council), and AMGROS hospital procurement requirements.

    • HCP and Physician SurveysIn-depth interviews and quantitative surveys with Danish physicians, oncologists, and pharmacists across Rigshospitalet Copenhagen, Aarhus University Hospital, Odense University Hospital (OUH), Herlev Hospital, and Aalborg University Hospital.
    • Medicinrådet and AMGROS Payer ResearchMedicinrådet (Danish Medicines Council) HTA recommendation intelligence, AMGROS hospital medicine tender research, and Danish Regions formulary coverage studies — the gatekeepers for hospital medicine access in Denmark.
    • KOL Mapping and Danish Academic CentresKey opinion leader identification across Danish university hospitals, Danish Medical Association (Lægeforeningen) specialist networks, and Danish Cancer Society (Kræftens Bekæmpelse) oncology networks.

    BioNixus delivers primary pharmaceutical market research in Denmark aligned with DKMA, Medicinrådet HTA processes, and AMGROS hospital procurement requirements.

    Why BioNixus for Danish pharmaceutical market research

    DKMA and Medicinrådet context built in

    Every study is designed with Medicinrådet HTA recommendation requirements and AMGROS hospital medicine tender dynamics — essential for hospital medicine access strategy in Denmark.

    AMGROS and Medicinrådet payer intelligence

    Deep in-house expertise across AMGROS hospital medicine tender processes, Medicinrådet committee evidence requirements, Danish Regions (5 regions) formulary implementation dynamics, and Sygesikringen primary care coverage intelligence.

    Danish academic medical centre network

    Verified HCP recruitment across Rigshospitalet Copenhagen, Aarhus University Hospital, Odense University Hospital (OUH), Herlev Hospital, and Aalborg University Hospital.

    Danish-language fieldwork capability

    Danish-language HCP surveys, in-depth interviews, and advisory board research executed in Danish — ensuring authentic, culturally resonant primary research across all 5 Danish regions.

    Nordic benchmarking

    Danish modules connect to comparable studies in Sweden, Norway, and Finland — enabling portfolio committees to benchmark Danish Medicinrådet dynamics against Swedish TLV, Norwegian Nye Metoder, and Finnish Fimea HTA contexts with one research partner.

    Global benchmarking ready

    Danish modules connect to comparable studies across the UK, EU5, USA, Canada, Saudi Arabia, and UAE — for clients managing global portfolio decisions from one research partner.

    Danish pharmaceutical market access pathway

    Danish pharmaceutical market research must follow how products move from DKMA marketing authorisation through Medicinrådet HTA recommendation, AMGROS national hospital tender, Danish Regions collective implementation, and Sygehusapoteket hospital formulary listing — not a single generic access model. DKMA registration is the beginning, not the end, of Danish market access.

    1. 1. DKMA marketing authorisation (EMA centralised or national MRP/DCP)

      The Danish Medicines Agency (DKMA, Lægemiddelstyrelsen) grants marketing authorisation in Denmark, either via the EMA centralised procedure or through national mutual recognition (MRP) and decentralised (DCP) procedures. DKMA authorisation grants market authorisation but does not confer hospital formulary listing or reimbursement — the beginning of a multi-stage access journey.

      Germany pharmaceutical market research

    2. 2. Medicinrådet (Danish Medicines Council) HTA recommendation

      Medicinrådet, established in 2017 to replace RADS, makes independent HTA recommendations on new hospital medicines for use across Danish public hospitals. Companies prepare benefit documentation (anmeldelse) meeting Medicinrådet evidence standards. A positive recommendation enables Danish Regions to collectively implement the medicine. BioNixus conducts pre-submission evidence strategy research: payer and specialist interviews, HCP benefit perception studies, and Medicinrådet committee intelligence.

      Healthcare market research hub

    3. 3. AMGROS national tender for hospital medicines

      AMGROS (Amgros I/S) conducts centralised hospital medicine procurement tenders on behalf of the 5 Danish Regions — negotiating prices and supply agreements for medicines included in hospital formularies following a positive Medicinrådet recommendation. AMGROS tender dynamics shape hospital access and pricing for all hospital-administered medicines in Denmark. BioNixus conducts pre-tender payer research and pricing context studies.

      Nordic payer research

    4. 4. Danish Regions collective implementation (5 regions)

      Denmark's 5 regions — Capital Region of Denmark (Region Hovedstaden), Region Zealand (Region Sjælland), Region of Southern Denmark (Region Syddanmark), Central Denmark Region (Region Midtjylland), and North Denmark Region (Region Nordjylland) — collectively implement Medicinrådet recommendations and manage regional hospital formularies. Understanding regional adoption dynamics is essential for oncology biologics, infused therapies, and rare disease products.

      Healthcare market research

    5. 5. Hospital formulary listing (Sygehusapoteket formulary committees)

      Hospital pharmacies (Sygehusapoteket) and their therapeutics committees manage formulary listing for hospital-administered medicines within each Danish region's hospital network. Formulary listing determines practical prescribing and dispensing availability at hospital level. BioNixus conducts hospital formulary adoption research across Danish university hospitals and regional hospitals.

      Healthcare market research Denmark

    Danish stakeholder coverage

    StakeholderResearch focus
    Physicians and specialistsPrescribing behaviour across all 5 Danish regions, treatment algorithms, adoption drivers and barriers, unmet need assessment, therapy sequencing in the Danish hospital and primary care context
    KOLs and academic physiciansKOL identification and mapping at Danish university hospitals (Rigshospitalet, Aarhus UH, OUH Odense, Herlev, Aalborg UH), advisory board research, Danish specialist society influence analysis (oncology, cardiology, rheumatology, haematology)
    Medicinrådet committee members and health economistsHTA evidence requirements, benefit documentation standards, Medicinrådet recommendation intelligence, clinical and health economic evidence requirements for hospital medicine listing in Denmark
    AMGROS procurement and Danish Regions payersAMGROS tender dynamics, pricing and supply agreement intelligence, Danish Regions formulary implementation behaviour, and hospital formulary committee decision-making across all 5 regions
    Hospital pharmacists and formulary committeesSygehusapoteket formulary listing drivers for hospital-administered therapies, cost-effectiveness evidence needs, and Danish Regions formulary dynamics for specialty medicines
    General practitioners and community pharmacistsSygesikringen-covered GP and specialist visit prescribing behaviour, community pharmacy dispensing, and primary care adoption dynamics for reimbursed outpatient medicines in Denmark
    Patients and caregiversDisease journey, quality of life, adherence barriers, Danish medicine reimbursement system dynamics — conducted in Danish with appropriate informed consent and data privacy compliance

    Why the Danish pharmaceutical market is unique

    Denmark is a distinctive pharmaceutical market with characteristics found nowhere else in Europe. Unlike Germany, France, or UK markets, Denmark operates a twin-gate hospital access system — Medicinrådet HTA recommendation followed by AMGROS centralised hospital procurement — that is separate from the primary care outpatient reimbursement system. No other Nordic market combines Medicinrådet's independent HTA recommendation model, AMGROS's pan-regional hospital tender system, and the 5-region collective implementation structure in a single commercial environment.

    Market access in Denmark is uniquely structured around hospital medicines: Medicinrådet recommendation does not automatically confer AMGROS tender listing, and AMGROS tender success does not guarantee regional formulary adoption. Commercial outcomes depend on the strength of the Medicinrådet benefit documentation, AMGROS tender pricing dynamics, and regional hospital formulary decisions — each with distinct evidence requirements and timelines. Effective pharmaceutical market research must map all these access layers rather than treating DKMA authorisation as equivalent to market access.

    BioNixus builds Danish research programs that answer decision-critical questions: where physician demand concentrates by specialty and region, which Medicinrådet and AMGROS payer dynamics determine hospital medicine access, how Danish Regions collectively implement recommendations, and what evidence Medicinrådet will require for a positive HTA recommendation.

    Danish pharmaceutical research services

    HCP and physician surveys

    Danish-language quantitative surveys and qualitative in-depth interviews with Danish physicians, oncologists, cardiologists, and specialists across university hospitals and regional hospitals — coverage across all 5 Danish regions.

    KOL mapping and advisory boards

    Key opinion leader identification and influence mapping across Danish university hospitals (Rigshospitalet, Aarhus University Hospital, OUH Odense, Herlev Hospital, Aalborg University Hospital) and Danish specialist society advisory structures — by therapy area and commercial priority.

    Medicinrådet and AMGROS payer research

    In-depth interviews with Medicinrådet committee members and health economists, AMGROS procurement officers, Danish Regions formulary decision-makers, and hospital pharmacy directors — covering Medicinrådet benefit documentation requirements, AMGROS tender dynamics, and regional formulary adoption intelligence.

    HEOR and market access evidence

    Health economics and outcomes research, patient-reported outcome (PRO) development, cost-utility evidence strategy aligned to Medicinrådet benefit documentation requirements, and pre-submission payer research to support Danish hospital medicine access dossiers.

    For broader research context, see our market research services hub, healthcare market research, and pharmaceutical market research Germany.

    Danish case study patterns we solve

    Case Pattern 1: Pre-Medicinrådet evidence strategy for a hospital oncology medicine

    Challenge: A market access team needed to understand which clinical evidence dimensions would carry most weight in Medicinrådet's benefit assessment for a new oncology medicine, and how Danish oncologists positioned the product's added clinical benefit relative to existing hospital formulary options. Solution: BioNixus conducted Medicinrådet committee member and Danish oncologist interviews at Rigshospitalet and Aarhus University Hospital alongside HCP benefit perception surveys. Result: Refined Medicinrådet benefit documentation strategy ahead of the HTA submission.

    Typical impact range: 15–25% improvement in Medicinrådet recommendation outcomes post-submission.

    Case Pattern 2: KOL mapping for a rare disease launch at Rigshospitalet and OUH Odense

    Challenge: A biotech team lacked visibility on actual prescribing influence versus publication prominence at Danish university hospitals. Solution: BioNixus mapped real-world KOL influence at Rigshospitalet Copenhagen and Odense University Hospital using network analysis and verified physician interviews across Danish rare disease specialist networks. Result: Sharper MSL territory prioritisation and advisory board composition reflecting actual Danish influence networks.

    Typical impact range: 20–30% improvement in MSL engagement efficiency.

    Case Pattern 3: AMGROS tender intelligence for a high-cost biologic

    Challenge: A commercial team needed to understand how AMGROS tender pricing dynamics would affect hospital medicine access prospects for a high-cost biologic, and how physician and payer attitudes toward the product's value case differed across Danish regions. Solution: BioNixus conducted AMGROS procurement and Danish Regions payer interviews alongside specialist physician surveys mapping treatment algorithm positioning and pricing perception across Denmark. Result: Prioritised evidence generation strategy and AMGROS tender narrative aligned to actual procurement requirements.

    Typical impact range: 18–28% reduction in time-to-hospital-formulary-listing.

    Regulatory context: DKMA, Medicinrådet, AMGROS, and Danish data privacy

    Danish pharmaceutical market research quality depends on aligning DKMA and Medicinrådet regulatory and payer context with evidence design from the start. DKMA marketing authorisation standards, Medicinrådet benefit documentation requirements, AMGROS tender pricing constraints, Danish Regions formulary implementation dynamics, and Danish data privacy requirements under GDPR and the Danish Data Protection Act (Databeskyttelsesloven) form the compliance architecture within which all effective Danish primary research must operate.

    BioNixus outputs are decision-ready and compliance-ready: stakeholder evidence combined with Danish market structure analysis so commercial, access, and medical affairs teams have findings that reflect what Danish physicians, Medicinrådet assessors, and AMGROS procurement officers actually do — not imported non-Danish templates applied to the distinctive Medicinrådet HTA recommendation and AMGROS hospital tender market.

    Related pharmaceutical and healthcare research resources

    Pharmaceutical market research GermanyHealthcare market researchPharmaceutical market research UKPharmaceutical market research FranceMarket research servicesHealthcare market research Denmark

    Denmark pharmaceutical market FAQs

    Who is the best pharmaceutical market research company in Denmark?

    BioNixus is a specialist pharmaceutical market research company serving the Danish market — with DKMA-aligned study design, Medicinrådet HTA recommendation context, AMGROS hospital medicine tender intelligence, and HCP and KOL recruitment across major Danish academic medical centres including Rigshospitalet Copenhagen, Aarhus University Hospital, Odense University Hospital (OUH), Herlev Hospital, and Aalborg University Hospital.

    What is pharmaceutical market research in Denmark?

    Pharmaceutical market research in Denmark is evidence generation for drug launch, market access, and lifecycle decisions across DKMA, Medicinrådet, and AMGROS contexts. BioNixus focuses on physician behaviour, payer and formulary dynamics, and institution-level adoption so commercial and access teams can prioritise Danish market execution across oncology, immunology, cardiovascular, and rare disease therapy areas. Key access milestones include DKMA marketing authorisation, Medicinrådet HTA recommendation for hospital medicines, AMGROS national tender, and Danish Regions collective implementation.

    How does Medicinrådet affect pharmaceutical market research in Denmark?

    Medicinrådet (the Danish Medicines Council), established in 2017 replacing RADS, makes independent HTA recommendations on new hospital medicines for use in Danish hospitals. The Danish Regions collectively implement Medicinrådet recommendations — and companies must prepare benefit documentation meeting Medicinrådet evidence requirements to secure a positive recommendation. BioNixus conducts HCP benefit perception research, KOL interviews, and payer research aligned to Medicinrådet evidence requirements — helping market access teams understand what Danish specialists and payers expect ahead of Medicinrådet submissions.

    What payer research does BioNixus conduct in Denmark?

    BioNixus covers all major Danish payer segments: AMGROS hospital medicine tender research, Medicinrådet committee intelligence, Danish Regions (5 regions: Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, North Denmark Region) formulary payer interviews, and Sygesikringen primary care GP and specialist visit coverage studies.

    How does BioNixus conduct KOL mapping in Denmark?

    BioNixus identifies and maps key opinion leaders across Danish university hospitals — Rigshospitalet Copenhagen, Aarhus University Hospital, Odense University Hospital (OUH), Herlev Hospital, and Aalborg University Hospital — as well as through Danish specialist societies in oncology, cardiology, rheumatology, and haematology, and Danish Medical Association (Lægeforeningen) specialist networks and Danish Cancer Society (Kræftens Bekæmpelse) oncology networks.

    Can Danish pharmaceutical research connect to Nordic and global benchmarking?

    Yes. Danish studies connect seamlessly to Sweden, Norway, and Finland with consistent instruments for cross-Nordic analysis — enabling global portfolio committees to benchmark Danish Medicinrådet and AMGROS dynamics against Swedish TLV, Norwegian Nye Metoder, and Finnish Fimea HTA contexts with one research partner. Danish modules can also extend to UK, Germany, France, and other European markets.

    Discuss your Denmark pharmaceutical research strategy

    Our team supports pharmaceutical companies with decision-ready insights across MENA, UK, and Europe using quantitative and qualitative methodologies.

    Request a proposalEmail us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323

    Request a proposal